SEC Filing Summary: Bioanalytical Systems, Inc. (10-Q)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Bioanalytical Systems, Inc. (Note: Metadata listed "Inotiv, Inc." but the filing text identifies the registrant as Bioanalytical Systems, Inc.) for the period ended December 31, 2008. The company provides contract laboratory research services and manufactures scientific instruments for pharmaceutical development. The company operates two segments: Research Services and Research Products. In June 2008, the company sold its Clinical Pharmacology Research Unit (CPRU), which is now reported as discontinued operations.
Key Financial Metrics
| Metric | Q1 2009 (Ended Dec 31, 2008) | Q1 2008 (Ended Dec 31, 2007) |
|---|---|---|
| Total Revenue | $8,076,000 | $10,565,000 |
| Gross Profit | $2,047,000 (25.3% margin) | $4,086,000 (38.7% margin) |
| Operating Income (Loss) | $(1,574,000) | $1,281,000 |
| Net Loss | $(1,584,000) | $(16,000) |
| Cash and Equivalents | $451,000 | $641,000 (End of period) |
| Revolving Credit Outstanding | $1,647,000 | $0 (Not reported in prior period balance sheet) |
| Long-Term Debt | $8,587,000 | $8,715,000 |
| Operating Cash Flow | $265,000 | $2,713,000 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 23.6% year-over-year. Service revenue dropped 25.5% due to study delays and cancellations in bioanalytical analysis and toxicology. Product revenue fell 17.4%, driven by a 47.1% drop in sales of Culex automated sampling systems.
- Margin Compression: Gross margin declined from 38.7% to 25.3%. The cost of service revenue as a percentage of revenue increased to 88.3% from 67.8% due to lower absorption of fixed costs amidst declining sales.
- Operating Loss: The company swung from an operating profit of $1.28 million to a loss of $1.57 million. This was driven by the revenue decline and a 31.4% increase in General and Administrative expenses (due to severance, new management hiring, and foreign currency losses).
- Discontinued Operations: The prior year included a net loss of $603,000 from the CPRU unit, which was sold in June 2008. The current quarter shows no activity from discontinued operations.
Outlook, Risks, and Contingencies
- Liquidity and Debt Covenants: The company is currently not in compliance with fixed charge coverage and debt service coverage ratios under its credit agreements with National City Bank and Regions Bank. While Regions Bank granted a waiver in February 2009, National City Bank has not yet completed its review. Failure to obtain a waiver could result in an acceleration of debt, severely impairing operations.
- Market Conditions: Management cites global economic and credit market disruptions as primary drivers for reduced client spending on CRO services. They anticipate negative impacts on revenue and cash flow to continue through the second quarter of fiscal 2009.
- Cost Reduction: In January 2009, the company completed a reduction in force expected to reduce annual compensation expenses by approximately 12%.
- Internal Controls: The company identified a material weakness in internal controls over financial reporting related to income tax accounting (FIN 48 adoption errors). As of December 31, 2008, the remediation software had not yet been implemented.
- Contingent Liability: The company remains contingently liable for up to $800 annually through 2015 regarding the lease of the sold CPRU facility if the buyer fails to meet obligations.
Investor Verification Checklist
- Debt Covenant Status: Verify the final status of the waiver request with National City Bank and the terms of any new covenants imposed.
- Cash Burn Rate: Monitor operating cash flow trends given the projected continued decline in sales and the freeze on capital expenditures.
- Revenue Recovery: Assess whether the decline in new bookings and study delays is stabilizing or worsening in the second quarter.
- Internal Control Remediation: Confirm the implementation timeline for the software intended to fix the material weakness in tax accounting.
- Discontinued Operations: Review the collection status of receivables from the sold CPRU unit to ensure no unexpected liabilities arise.